Erucylphosphocholine: Pharmacokinetics, biodistribution and CNS- accumulation in the rat after intravenous administration

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 6, 1999, Pages 484-490

  Erdlenbruch, Bernhard ^a   Jendrossek, Verena ^a   Gerriets, Angela ^a   Vetterlein, Friedrich ^b   Eibl, Hansjörg ^c   Lakomek, Max ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

Alkylphosphocholines; Biodistribution; Chemotherapy; Erucylphosphocholine (ErPC); Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CHOLINE DERIVATIVE; ERUCYLPHOSPHOCHOLINE; UNCLASSIFIED DRUG;

ADRENAL GLAND; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BRAIN; BRAIN TUMOR; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG STRUCTURE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; BODY WEIGHT; BRAIN; INJECTIONS, INTRAVENOUS; LEUKOCYTE COUNT; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHOSPHORYLCHOLINE; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 0032708966     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051122     Document Type: Article

References (29)

1. 1. Andreesen R, Modolell M, Weltzien HU, Eibl H, Common HH, Löhr GW, Munder PG (1978) Selective destruction of human leukemic cells by alkyl-lysophospholipids. Cancer Res 38: 3894
2. 2. Arnold B, Reuther R, Weltzien HU (1978) Distribution and metabolism of synthetic alkyl analogues of lysophosphatidylcholine in mice. Biochim Biophys Acta 530: 47
3. 3. Baumann WJ, Berdel WE, Bosch H van den, Eibl H, Hermann DBJ, Munder PG, Snyder FL, Unger C (eds) (1987) First international symposium on ether lipids in oncology. Lipids 22: 787
4. 4. Berdel WE, Greiner E, Fink U, Zänker KS, Stavrou D, Trappe A, Fahlbusch R, Reichert A, Rastetter J (1984) Cytotoxic effects of alkyl-lysophospholipids in human brain tumor cells. Oncology 41: 140
5. 5. Berdel WE, Becher R, Edler L, Bremer K, Essers U, Drozd A, Zafferani M, Klee MAG, Bachmann P, Korfel A, Westerhausen M (1992) Daily oral miltefosine (hexadecylphosphocholine) in patients with advanced non-small cell lung cancer. A phase II study. Onkologie 15: 238
6. 6. Berger MR, Eibl H (1992) Erucylphosphocholine is a second generation alkylphosphocholine (APC). Proc Am Assoc Cancer Res 33: 416
7. 7. Berger MR, Betsch B, Gebelein M, Amtmann E, Heyl P, Scherf HR (1993) Hexadecylphosphocholine differs from conventional cytostatic agents. J Cancer Res Clin Oncol 119: 541
8. 8. Breiser A, Kim D-J, Fleer EAM, Damenz W, Drube A, Berger M, Nagel GA, Eibl H, Unger C (1987) Distribution and metabolism of hexadecylphosphocholine in mice. Lipids 22: 925
9. 9. Eibl H, Kaufmann-Kolle P (1995) Medical application of synthetic phospholipids as liposomes and drugs. J Liposome Res 5: 131
10. 10. Eibl H, Unger C (1990) Hexadecylphosphocholine, a new and selective antitumor drug. Cancer Treat Rev 17: 233
11. 11. Erdlenbruch B, Jendrossek V, Marx M, Hunold A, Eibl H, Lakomek M (1998) Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo. Anticancer Res 18: 2551
12. 12. Fleer EAM, Kim D-J, Nagel GA, Eibl H, Unger C (1990) Cytotoxic activity of lysophosphatidylcholine analogues on human lymphoma raji cells. Oncology 13: 295
13. 13. Harms PG, Ojeda SR (1974) A rapid and simple method for chronic cannulation of the jugular vein. J Appl Physiol 36: 391
14. 14. Hilgard P, Stekar J, Voegeli R, Engel J, Schumacher W, Eibl H, Unger C, Berger M (1988) Characterization of the antitumor activity of hexadecylphosphocholine (D18506). Eur J Clin Oncol 24: 1457
15. 15. Hilgard P, Stekar J, Unger C (1991) Miltefosine counteracts bone marrow toxicity and improves therapeutic effects of cyclophosphamide. Proc Am Assoc Cancer Res 32: 380
16. 16. Jendrossek V, Erdlenbruch B, Hunold A, Kugler W, Eibl H, Lakomek M (1999) Erucylphosphocholine, a novel antineoplastic ether lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro. Int J Oncol 14: 15
17. 17. Kaufmann-Kolle P, Kötting J, Drevs J, Berger MR, Unger C, Eibl H (1992) Intravenous application of alkylphosphocholines: comparison of different homologues in lamellar structures. J Cancer Res Clin Oncol 120 [Suppl]: R14
18. 18. Kaufmann-Kolle P, Drevs J, Berger MR, Kötting J, Marschner N, Unger C, Eibl H (1994) Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine. Cancer Chemother Pharmacol 34: 393
19. 19. Kötting J, Marschner NW, Neumüller W, Unger C, Eibl H (1992) Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution. In: Eibl H, Hilgard P, Unger C (eds) Alkylphosphocholines: new drugs in cancer therapy (Progress in experimental tumor research, vol 34). Karger-Verlag, Basel, p 131
20. 20. Kötting J, Berger MR, Unger C, Eibl H (1992) Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations. Cancer Chemother Pharmacol 30: 105
21. 21. Magistrelli A, Villa P, Benfenati E, Modest EJ, Salmona M, Tacconi MT (1995) Fate of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET18-OMe) in malignant cells, normal cells and isolated and perfused rat liver. Drug Metab Dispos 23: 113
22. 22. Marschner N, Kötting J, Eibl H, Unger C (1992) Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment. Cancer Chemother Pharmacol 31: 18
23. 23. Planting A, Stoter G, Verweij J (1993) Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur J Cancer 29: 518
24. 24. Sobottka SB, Berger MR (1992) Assessment of antineoplastic agents by MTT assay: partial underestimation of antiproliferative properties. Cancer Chemother Pharmacol 30: 385
25. 25. Sobottka SB, Berger MR, Eibl H (1993) Structure-activity relationships of four anti-cancer alkylphosphocholine derivatives in vitro and in vivo. Int J Cancer 53: 418
26. 26. Unger C, Damenz W, Fleer EAM, Kim DJ, Breiser A, Hilgard P, Engel J, Nagel G, Eibl H (1989) Hexadecylphosphocholine, a new ether lipid analogue. Acta Oncol 28: 213
27. 27. Vehmeyer K, Kim D-J, Nagel GA, Eibl H, Unger C (1989) Effect of ether lipids on mouse granulocyte-macrophage pro-genitor cells. Cancer Chemother Pharmacol 24: 58
28. 28. Verweij J, Planting AST (1991) Leuco- and thrombocytosis induced by the ether lipid hexadecylphosphocholine (HePC). Proc Am Soc Clin Oncol 10: 117
29. 29. Verweij J, Planting A, Van der Burg M, Stoter G (1992) A dose finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. J Cancer Res Clin Oncol 118: 606